289 560

Cited 4 times in

Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension

 Dae-Won Sohn  ;  Hyung-Kwan Kim  ;  Myung-A Kim  ;  Yeong-Wook Song  ;  Chung-Il Noh  ;  Duk-Kyung Kim  ;  I-Seok Kang  ;  Hojoong Kim  ;  Sang-Do Lee  ;  Young-Hwue Kim  ;  Ho-Joong Youn  ;  Namsik Chung  ;  Jae-Young Choi  ;  Jae-Bum Jun  ;  Jinho Shin 
 KOREAN CIRCULATION JOURNAL, Vol.39(3) : 105-110, 2009 
Journal Title
Issue Date
Hypertension ; pulmonary ; Bosentan ; Adverse effects
BACKGROUND AND OBJECTIVES: The purpose of this study was to investigate 1) the beneficial effect of bosentan treatment (125 mg twice daily) on exercise capacity and echocardiographic variables and 2) the profiles and frequency of adverse events in Korean patients with World Health Organization (WHO) class III or IV pulmonary artery hypertension (PAH).

SUBJECTS AND METHODS: Twelve patients who received bosentan treatment were investigated in an open label manner. One patient was excluded in the final analyses due to a prohibited concomitant medication. A 6-minute walk test and echocardiography were performed at baseline and after 12 weeks of treatment.

RESULTS: The administration of bosentan for 12 weeks resulted in a significant improvement in exercise capacity (measured with the 6-minute walking distance), WHO functional capacity, and in echocardiographic variables. Bosentan treatment was associated with a decrease in the maximal tricuspid regurgitation jet velocity {from 4.7 m/sec (95% confidence interval, 3.89-5.45) at baseline to 4.4 m/sec (95% confidence interval, 3.61-5.1) at 12 weeks, p=0.03} and systolic pulmonary arterial pressure {from 105 mmHg (95% confidence interval, 74.4-135.6) at baseline to 93 mmHg (95% confidence interval, 66.3-120.1) at 12 weeks, p=0.04}. Treatment with bosentan at a dose of 125 mg twice a day was not associated with life-threatening side effects, although a higher incidence of elevated liver enzymes compared to previous studies was noted.

CONCLUSION: Bosentan at a dose of 125 mg twice daily is considered a clinically optimal, safe dose and can be used as a valuable treatment option in Korean PAH patients with WHO functional capacity III or IV, though close monitoring of liver function is required.
Files in This Item:
T200903395.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Nam Sik(정남식)
Choi, Jae Young(최재영) ORCID logo https://orcid.org/0000-0002-1247-6669
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.